Condition
Dyskinesia, Medication-Induced
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05297201Phase 2Completed
Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia
NCT04147949Phase 2Unknown
AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia
NCT02657681Phase 2CompletedPrimary
Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)
NCT00175955Phase 2CompletedPrimary
Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
Showing all 4 trials